{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:08:41Z","timestamp":1791950921127,"version":"4.3.4"},"reference-count":22,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["7025-21"],"award-info":[{"award-number":["7025-21"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia & Lymphoma Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"NIH National Cancer Institute","doi-asserted-by":"publisher","award":["1U01CA232490-01"],"award-info":[{"award-number":["1U01CA232490-01"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.bneo.2026.100232","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T16:13:12Z","timestamp":1776269592000},"page":"100232","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Fully human anti-FOLR1 T-cell engager demonstrates potent activity in CBFA2T3::GLIS2 acute megakaryoblastic leukemia"],"prefix":"10.1016","volume":"3","author":[{"given":"Shelli M.","family":"Morris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Pilat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily J.","family":"Girard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8823-313X","authenticated-orcid":false,"given":"Alyssa","family":"Noll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6140-4330","authenticated-orcid":false,"given":"Lisa S.","family":"Ang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4743-5919","authenticated-orcid":false,"given":"Jason","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Mhyre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin E.","family":"Correnti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashok D.","family":"Bandaranayake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Mehlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2402-108X","authenticated-orcid":false,"given":"Midori","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Brasel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parvathi","family":"Muthuraman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary R.","family":"Crook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3471-1949","authenticated-orcid":false,"given":"Bonnie","family":"Cole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany A.","family":"Hylkema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quy","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soheil","family":"Meshinchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5990-6534","authenticated-orcid":false,"given":"James M.","family":"Olson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.bneo.2026.100232_bib1","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.ccr.2012.10.007","article-title":"An inv(16)(p13.3q24.3)-encoded CBFA2T3-GLIS2 fusion protein defines an aggressive subtype of pediatric acute megakaryoblastic leukemia","volume":"22","author":"Gruber","year":"2012","journal-title":"Cancer Cell"},{"issue":"10","key":"10.1016\/j.bneo.2026.100232_bib2","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1038\/leu.2017.51","article-title":"AMKL chimeric transcription factors are potent inducers of leukemia","volume":"31","author":"Dang","year":"2017","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.bneo.2026.100232_bib3","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/bjh.15725","article-title":"CBFA2T3-GLIS2-positive acute myeloid leukaemia. A peculiar paediatric entity","volume":"184","author":"Masetti","year":"2019","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.bneo.2026.100232_bib4","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1182\/blood-2015-05-567859","article-title":"The biology of pediatric acute megakaryoblastic leukemia","volume":"126","author":"Gruber","year":"2015","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bneo.2026.100232_bib5","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/ng.3772","article-title":"Pediatric non-Down syndrome acute megakaryoblastic leukemia is characterized by distinct genomic subsets with varying outcomes","volume":"49","author":"de Rooij","year":"2017","journal-title":"Nat Genet"},{"issue":"22","key":"10.1016\/j.bneo.2026.100232_bib6","doi-asserted-by":"crossref","first-page":"5933","DOI":"10.1182\/bloodadvances.2022008503","article-title":"Targeting FOLR1 in high-risk CBF2AT3-GLIS2 pediatric AML with STRO-002 FOLR1-antibody-drug conjugate","volume":"6","author":"Tang","year":"2022","journal-title":"Blood Adv"},{"issue":"22","key":"10.1016\/j.bneo.2026.100232_bib7","doi-asserted-by":"crossref","DOI":"10.1172\/JCI157101","article-title":"CBFA2T3-GLIS2 model of pediatric acute megakaryoblastic leukemia identifies FOLR1 as a CAR T cell target","volume":"132","author":"Le","year":"2022","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.bneo.2026.100232_bib8","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/s41416-022-02031-x","article-title":"Folate receptor alpha in ovarian cancer tissue and patient serum is associated with disease burden and treatment outcomes","volume":"128","author":"Bax","year":"2023","journal-title":"Br J Cancer"},{"key":"10.1016\/j.bneo.2026.100232_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2023.121802","article-title":"Recent advances in using folate receptor 1 (FOLR1) for cancer diagnosis and treatment, with an emphasis on cancers that affect women","volume":"326","author":"Varaganti","year":"2023","journal-title":"Life Sci"},{"issue":"3","key":"10.1016\/j.bneo.2026.100232_bib10","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1158\/1078-0432.CCR-19-1800","article-title":"Comprehensive transcriptome profiling of cryptic CBFA2T3-GLIS2 fusion-positive AML defines novel therapeutic options: a COG and TARGET pediatric AML study","volume":"26","author":"Smith","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bneo.2026.100232_bib11","doi-asserted-by":"crossref","first-page":"1216516","DOI":"10.3389\/fddsv.2023.1216516","article-title":"Novel mesothelin antibodies enable crystallography of the intact mesothelin ectodomain and engineering of potent, T cell-engaging bispecific therapeutics","volume":"3","author":"Lin","year":"2023","journal-title":"Frontiers in Drug Discovery"},{"issue":"2","key":"10.1016\/j.bneo.2026.100232_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25021046","article-title":"Folate receptor alpha-a novel approach to cancer therapy","volume":"25","author":"Gonzalez","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"4416","key":"10.1016\/j.bneo.2026.100232_bib13","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1126\/science.314668","article-title":"Monoclonal antibodies defining distinctive human T cell surface antigens","volume":"206","author":"Kung","year":"1979","journal-title":"Science"},{"issue":"20","key":"10.1016\/j.bneo.2026.100232_bib14","doi-asserted-by":"crossref","first-page":"7675","DOI":"10.1073\/pnas.0402295101","article-title":"Crystal structure of the human T cell receptor CD3 epsilon gamma heterodimer complexed to the therapeutic mAb OKT3","volume":"101","author":"Kjer-Nielsen","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"issue":"534","key":"10.1016\/j.bneo.2026.100232_bib15","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax1315","article-title":"Interdomain spacing and spatial configuration drive the potency of IgG-[L]-scFv T cell bispecific antibodies","volume":"12","author":"Santich","year":"2020","journal-title":"Sci Transl Med"},{"issue":"12","key":"10.1016\/j.bneo.2026.100232_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0260954","article-title":"Fc-engineered antibodies with immune effector functions completely abolished","volume":"16","author":"Wilkinson","year":"2021","journal-title":"PLoS One"},{"issue":"21","key":"10.1016\/j.bneo.2026.100232_bib17","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkr706","article-title":"Daedalus: a robust, turnkey platform for rapid production of decigram quantities of active recombinant proteins in human cell lines using novel lentiviral vectors","volume":"39","author":"Bandaranayake","year":"2011","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"10.1016\/j.bneo.2026.100232_bib18","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/cpt.1961","article-title":"Mechanistic quantitative pharmacology strategies for the early clinical development of bispecific antibodies in oncology","volume":"108","author":"Betts","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.bneo.2026.100232_bib19","doi-asserted-by":"crossref","first-page":"4295","DOI":"10.1182\/blood-2023-180141","article-title":"4295 anti-leukemic activity of luveltamab tazevibulin (LT, STRO-002), a novel folate receptor-\u03b1 (FR-\u03b1)-targeting antibody drug conjugate (ADC) in relapsed\/refractory CBF2AT3::GLIS2 AML. ASH Annual Meeting and Exposition","volume":"142","author":"Williams","year":"2023","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.bneo.2026.100232_bib20","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1038\/s41375-024-02387-4","article-title":"Evolution of T-cell fitness through AML progression: enhanced bispecific T-cell engager-mediated function of bone marrow T cells at remission compared to initial diagnosis and relapse","volume":"38","author":"Kazerani","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.bneo.2026.100232_bib21","doi-asserted-by":"crossref","first-page":"101031","DOI":"10.1016\/j.medj.2026.101031","article-title":"T cell exhaustion in bi- and trispecific T cell engager therapy in hematologic malignancies: mechanisms and implications","volume":"7","author":"Muth","year":"2026","journal-title":"Med"},{"issue":"1","key":"10.1016\/j.bneo.2026.100232_bib22","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2083479","article-title":"Novel strategies for the mitigation of cytokine release syndrome induced by T cell engaging therapies with a focus on the use of kinase inhibitors","volume":"11","author":"Leclercq","year":"2022","journal-title":"Oncoimmunology"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328026000439?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328026000439?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:16:23Z","timestamp":1790687783000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950328026000439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2950328026000439"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2026.100232","relation":{},"ISSN":["2950-3280"],"issn-type":[{"value":"2950-3280","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fully human anti-FOLR1 T-cell engager demonstrates potent activity in CBFA2T3::GLIS2 acute megakaryoblastic leukemia","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2026.100232","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100232"}}